Welcome to our dedicated page for Moderna news (Ticker: MRNA), a resource for investors and traders seeking the latest updates and insights on Moderna stock.
Moderna, Inc. reports developments in mRNA medicines, including commercial vaccines, investigational respiratory vaccines, oncology programs and rare-disease candidates. News commonly covers regulatory authorizations and agency interactions for products such as Spikevax, mRESVIA, mNEXSPIKE and mCOMBRIAX, as well as clinical data for seasonal influenza, pandemic influenza and cancer immunotherapy programs including intismeran autogene and mRNA-4359.
Company updates also include quarterly financial results, revenue mix, expense actions, strategic partnerships, scientific meeting presentations and intellectual-property matters tied to Moderna's infectious disease portfolio and broader mRNA technology platform.
Moderna (NASDAQ:MRNA) and the University of Oxford received UK MHRA authorization to begin a Phase 1/2 INTERCEPT-Lynch study of mRNA-4194, an investigational mRNA cancer vaccine for people with Lynch syndrome.
The trial will assess safety, immune response and dosing, within a broader 10-year UK strategic mRNA partnership.
Moderna (Nasdaq:MRNA) will present at the Goldman Sachs 47th Annual Global Healthcare Conference 2026 on Tuesday, June 9 at 3:20 p.m. ET.
A live webcast and a replay, available for at least 30 days, will be accessible in the Investors section of Moderna's website.
Merck (NYSE:MRK) and Moderna reported 5-year follow-up data from the Phase 2b KEYNOTE-942/mRNA-4157-P201 trial of intismeran autogene (mRNA-4157, V940) plus KEYTRUDA in high-risk stage III/IV melanoma after complete resection.
The combination reduced risk of recurrence or death by 49% and distant metastasis or death by 59% versus KEYTRUDA alone at a median 60.3-month follow-up, with a safety profile consistent with prior analyses.
Moderna (NASDAQ:MRNA) and CEPI expanded their collaboration to advance a potential Bundibugyo ebolavirus (BDBV) vaccine. CEPI committed up to $50 million to fund preclinical work, Phase 1 clinical testing, and parallel manufacturing using Moderna's mRNA platform.
The goal is to accelerate readiness for rapid progression to Phase 2/3 trials if Phase 1 safety and immunogenicity data support further development.
Moderna (NASDAQ:MRNA) was ranked no. 1 on TIME's 2026 list of the World's Most Impactful Companies, recognizing its mRNA leadership and societal impact. In 2026, Moderna gained European approval for mCOMBRIAX, its fourth product and first flu plus COVID combination vaccine.
The company is deepening long-term pandemic-preparedness partnerships with the UK, Canada and Australia, and expanding its mRNA Access program, which now includes 35 institutions exploring vaccines for emerging and neglected infectious diseases.
Moderna (NASDAQ:MRNA) announced a New England Journal of Medicine publication of Phase 3 P304 data for its seasonal influenza vaccine candidate mRNA-1010 on May 6, 2026. The study showed an overall relative vaccine efficacy (rVE) versus a licensed standard-dose vaccine of 26.6% (95% CI 16.7%–35.4%), with strain-specific rVEs: A/H1N1 29.6%, A/H3N2 22.2%, and B/Victoria 29.1%.
Subgroup analyses were consistent across ages and risk factors; in participants aged 65+, rVE was 27.4%. Regulatory reviews are underway in the U.S., Europe, Canada and Australia, with a U.S. PDUFA goal date of August 5, 2026.
Moderna (NASDAQ:MRNA) reported Q1 2026 revenue of $389 million and GAAP net loss of $(1.3) billion with GAAP EPS of $(3.40)/b, which included a
Regulatory updates include EU approvals for mCOMBRIAX (flu + COVID), mNEXSPIKE, and mRESVIA. Moderna initiated a Phase 3 study of intismeran in high-risk Stage 1 NSCLC and expects multiple pipeline readouts in 2026.
Moderna (NASDAQ:MRNA) announced dosing of the first U.S. and UK participants in a Phase 3 study of its investigational H5 pandemic influenza mRNA vaccine candidate, mRNA-1018, on April 21, 2026. The trial aims to enroll ~4,000 adults 18+ to evaluate safety and immunogenicity. CEPI committed up to $54.3 million in December 2025 to advance mRNA-1018 to licensure. Positive Phase 3 data would support global regulatory submissions alongside data from Moderna's seasonal candidate mRNA-1010, currently accepted for review in the U.S., EU, Canada and Australia. Moderna will reserve 20% of H5 manufacturing capacity for low- and middle-income countries if licensed.
Moderna (NASDAQ:MRNA) announced three abstracts accepted for presentation at the 2026 ASCO Annual Meeting (May 29–June 2, Chicago).
Presentations include a 5-year KEYNOTE-942 oral update on intismeran plus pembrolizumab in resected melanoma, two poster presentations including mRNA-2808 in multiple myeloma, and a live investor webcast on June 1 at 6:15 PM CDT. Intismeran autogene is jointly developed with Merck (MSD outside US/Canada).
Moderna (NASDAQ:MRNA) received European Commission marketing authorization for mCOMBRIAX (mRNA-1083) on April 21, 2026, the world's first combined influenza and COVID-19 mRNA vaccine for adults 50 and older. Phase 3 results met non-inferiority endpoints and showed higher immune responses versus co-administered comparators. The vaccine demonstrated an acceptable safety profile and will be rolled out across the EU subject to national regulatory and access procedures.